Journal
EUROPEAN CHILD & ADOLESCENT PSYCHIATRY
Volume 20, Issue 1, Pages 17-37Publisher
SPRINGER
DOI: 10.1007/s00787-010-0140-6
Keywords
ADHD; HKS; Medication; Adverse; Guidelines; European; Children
Categories
Funding
- Lilly
- Medice
- Novartis
- UCB
- Shire
- Medical Research Council [G9817803B] Funding Source: researchfish
Ask authors/readers for more resources
The safety of ADHD medications is not fully known. Concerns have arisen about both a lack of contemporary-standard information about medications first licensed several decades ago, and signals of possible harm arising from more recently developed medications. These relate to both relatively minor adverse effects and extremely serious issues such as sudden cardiac death and suicidality. A guidelines group of the European Network for Hyperkinetic Disorders (EUNETHYDIS) has therefore reviewed the literature, recruited renowned clinical sub-specialists and consulted as a group to examine these concerns. Some of the effects examined appeared to be minimal in impact or difficult to distinguish from risk to untreated populations. However, several areas require further study to allow a more precise understanding of these risks.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available